IMMX.US Immix Biopharma Inc

Healthcare Biotechnology USA Stocks
7.84 USD
Close of Nov 15, 2026
3.78 15.10
Market cap
USD 657M
P/E
-
P/B
1.96x
ROE
-14.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is IMMX.US undervalued?

Graham number

The Graham number of Immix Biopharma Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Immix Biopharma Inc fundamental analysis

No fundamental analysis for Immix Biopharma Inc yet.

Immix Biopharma Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Immix Biopharma Inc

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Full company profile